Reuters  Nov 12  Comment 
Aircraft components maker Aernnova's planned initial public offering could value the Spanish business at around 1.4 billion euros ($1.5 bln), two sources familiar with the matter...
Market Intelligence Center  Nov 4  Comment 
Option-trade picking algorithms patented by MarketIntelligenceCenter.com found a trading opportunity with St. Jude Medical Inc. (STJ) that should provide a 4.67% return in just 72 days. Sell one Jan. '16 call at the $65.00 level for each 100...
Forbes  Oct 21  Comment 
In early trading on Wednesday, shares of KLA-Tencor (KLAC) topped the list of the day's best performing components of the S&P 500 index, trading up 24.3%. Year to date, KLA-Tencor has lost about 4.8% of its value.
newratings.com  Oct 21  Comment 
WASHINGTON (dpa-AFX) - St. Jude Medical Inc. (STJ) released earnings for third quarter that fell compared to the same period last year. The company said its earnings came in at $277 million, or $0.97 per share. This was down from $296 million,...
Market Intelligence Center  Oct 19  Comment 
The patented algorithms that power MarketIntelligenceCenter.com's Artificial Intelligence Center found a trading opportunity with St. Jude Medical Inc. (STJ) that should provide a 6.46% return in just 88 days. Sell one Jan. '16 call at the $70.00...
newratings.com  Oct 12  Comment 
WASHINGTON (dpa-AFX) - St. Jude Medical, Inc. (STJ) announced the company has received CE Mark approval for the HeartMate 3 Left Ventricular Assist System, a cardiac support option for advanced heart failure patients who are awaiting...
Benzinga  Oct 7  Comment 
Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced today that all proposals necessary for St. Jude Medical, Inc.'s acquisition of Thoratec...


St. Jude Medical (NYSE:STJ) makes devices for cardiovascular and neurological conditions, including mechanical heart valves, pacemakers, and catheters. The company generates the majority of its revenue from its Cardiac Rhythm Management (CRM) division, which makes implantable cardiac rhythm devices (ICDs) and pacemakers. The company earned $4.7 billion in revenue and $777 million in 2009.[1]

St. Jude is dependent on the market for implantable cardiac defibrillators; roughly one-third of the company's revenue came from its ICD business. Sales of ICDs have have stagnated in recent years. Several studies suggest that a majority of patients eligible to receive ICDs don't actually receive referrals for the devices from their doctors, implying that the market for ICDs may be smaller than initially estimated by ICD manufacturers.

Company Overview

Business Segments[2]

St. Jude has four main business segments: Cardiac Rhythm Management (CRM), Cardiovascular, Neuromodulation, and Atrial Fibrillation.

  • Cardiac Rhythm Management (59% of net sales) includes two main products -- Implantable Cardiac Rhythm Devices (ICDs) and pacemakers. ICDs treat patients with hearts that beat inappropriately fast and pacemakers treat patients with hearts that beat too slowly. These devices are in patients suffering from lethal heart conditions such as sudden cardiac arrest.
  • Cardiovascular (20% of net sales) focuses on both cardiology and cardiac surgery therapy areas. This segment includes products such as heart valves and heart valve repair products, which are used during heart valve surgeries. St. Jude mechanical heart valves have been implanted in over 1.8 million patients worldwide.
  • Atrial Fibrillation (AF) (14% of net sales) is a rapid and inconsistent heart rhythm that occurs in the heart. People suffering from AF may experience fatigue and shortness of breath, and AF has been shown to increase the risk of stroke. St. Jude has a line of AF products such as catheters and 3D hearth mapping system which help physicians diagnose and treat irregular heart rhythms.
  • Neuromodulation (7% of net sales) is generally used to manage sharp, intense and constant pain from nerve damage or nervous system disorders. It basically applies pacemaker-like technology to treat diseases such as chronic pain, Parkinson's, and epilepsy.

Business Growth

FY 2009 (ended January 2, 2010)[1]

  • Net sales increased 7.2% to $4.7 billion. Net sales increased in all of the company's business segments.
  • Net income more than doubled to $777 million.

Trends and Forces

Medicare approval drives neuromodulation segment

Health coverage is an important determining factor when patients and doctors choose among various treatment options. Medicare coverage is particularly significant in that it directly affects over forty million Americans, how much patients have to pay for St. Jude's products, and how much the company will receive in payments from Medicare. Medicare and other third party payors are emphasizing more cost-effective medical devices, by limiting the reimbursement they will cover. Furthermore, even if a new medical device is cleared by the FDA, St. Jude faces limited demand for the device until Medicare and other payors approve the device for reimbursement.

Saturation of Implantable Cardiac Rhythm Devices (ICD) Market

ICDs are stopwatch-sized devices that monitor the heart and deliver appropriate therapy when an abnormal heart rhythm is detected. St. Jude is the second largest producer of ICDs with 20% market share for ICDs and over $1.5 billion in ICD sales.[3] ICDs usage has grown substantially over the years, due to trial results which showed ICDs reduced death by 23% in people with moderate heart failure compared to those who did not receive ICDs. Analysts are concerned, however, that initial market estimates of market size may have been over stated. Growth has been well below industry projections and a study suggests that only one in four patients that are eligible for the device actually receive referrals from their primary care physicians .[4]


St. Jude faces competitors in each of its business segments:[5]

Cardiac Rhythm Management (CRM)

St. Jude is one of the three principal manufacturers and suppliers in the global Cardiac Rhythm Management (CRM) market. The company's two larger competitors in this market are:

Atrial Fibrillation Therapy

The atrial fibrillation therapy area is broadening to include multiple therapy methods that include drugs, delivery of diagnostic and ablation catheters, and implantable fibrillators among others. The company's primary competitors include:


In the neuromodulation market, St. Jude is one of three principal manufacturers of nerustimulation devices. The principal competitors are Boston Scientific (BSX) and Medtronic (MDT). The company also faces competition from smaller competitors:


  1. 1.0 1.1 STJ 2009 10-K "Consolidated Statements of Earnings" pg. 24
  2. STJ 2009 10-K "Principal Products" pg. 1-7
  3. STJ 2009 10-K Exhibit 13 "Cardiac Rhythm Management" pg. 7
  4. U.S. Department of Health and Human Services, Experts Debate Limits on Implanted Defibrillator Use
  5. STJ 2009 10-K "Competition" pg. 7-8
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki